SHANGHAI, China, Sept. 4 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. ("WuXi PharmaTech" or ''the Company''), the leading China- based pharmaceutical and biotechnology research and development outsourcing company, today announced that it will release unaudited financial results for the second quarter ended June 30, 2007 before the US market opens on Thursday, September 6, 2007.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )
The earnings release will be available on the investor relations page of its website at http://www.wuxipharmatech.com .
Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (Eastern) / 5:00 am (Pacific) / 8:00 pm (Beijing/Hong Kong) on Thursday, September 6, 2007 to discuss its 2007 second quarter financial results and recent business activity. The conference call may be accessed by calling (US) +1 718 354 1157 / (UK) +44 (0)20 7138 0815 / (HK) +852 3002 1616. A telephone replay will be available shortly after the call until October 5, 2007 at (US) +1 718 354 1112/ (UK) +44 (0)20 7806 1970 / (HK) +852 3002 1607, Passcode: 1468987.
A live webcast of the conference call and replay will be available on the Investor Relations page of WuXi PharmaTech's website at http://www.wuxipharmatech.com .
About WuXi PharmaTech
Founded in 2000, Shanghai-based WuXi PharmaTech is the leading China-based pharmaceutical and biotechnology R&D outsourcing company. As a research- driven and customer-focused company, WuXi PharmaTech provides pharmaceutical and biotechnology companies a broad and integrated portfolio of laboratory and research manufacturing services throughout the drug discovery and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. Its operations are grouped into two segments: laboratory services, consisting of discovery chemistry, service biology, analytical, pharmaceutical development and process development services, and manufacturing, focusing on manufacturing of advanced intermediates and active pharmaceutical ingredients for R&D use. In 2006, WuXi PharmaTech provided services to 70 pharmaceutical and biotechnology customers, including nine of the top ten pharmaceutical companies in the world, as measured by 2006 total revenues. For more information, please visit: http://www.wuxipharmatech.com .
For more information, please contact: Investor Contact: Dr. Hai Mi Vice President, Corporate Communications WuXi PharmaTech Co., Ltd Tel: +86-21-5046-3726 Email: ir@pharmatechs.com Investor Relations (US): Mahmoud Siddig Director Taylor Rafferty Tel: +1-212-889-4350 Email: Pharmatechs@taylor-rafferty.com Investor Relations (HK): Ruby Yim Managing Director Taylor Rafferty Tel: +852-3196-3712 Email: Pharmatechs@taylor-rafferty.com Media Contact: John Dooley Taylor Rafferty Tel: +1-212-889-4350 Email: Pharmatechs@taylor-rafferty.com
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, +1-888-776-6555 or +1-212-782-2840WuXi PharmaTech (Cayman) Inc.CONTACT: Dr. Hai Mi, Vice President, Corporate Communications of WuXiPharmaTech Co., Ltd, +86-21-5046-3726, or ir@pharmatechs.com; or InvestorRelations (US), Mahmoud Siddig, Director, +1-212-889-4350, or InvestorRelations (HK), or Ruby Yim, Managing Director, +852-3196-3712, or MediaContact, John Dooley, +1-212-889-4350, all of Taylor Rafferty,Pharmatechs@taylor-rafferty.com, for WuXi
Web site: http://www.pharmatechs.com/
